These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22463610)

  • 61. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 63. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 64. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight.
    Engeli S
    Handb Exp Pharmacol; 2012; (209):357-81. PubMed ID: 22249824
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.
    Nguyen T; Thomas BF; Zhang Y
    Curr Top Med Chem; 2019; 19(16):1418-1435. PubMed ID: 31284863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
    Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
    Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 69. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
    Bifulco M; Pisanti S
    Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
    [No Abstract]   [Full Text] [Related]  

  • 70. Cannabinoid receptor CB1 antagonists state of the art and challenges.
    Bifulco M; Santoro A; Laezza C; Malfitano AM
    Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The cannabinoid receptor 1 and its role in influencing peripheral metabolism.
    O'Keefe L; Simcocks AC; Hryciw DH; Mathai ML; McAinch AJ
    Diabetes Obes Metab; 2014 Apr; 16(4):294-304. PubMed ID: 23782485
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance.
    Tam J; Cinar R; Liu J; Godlewski G; Wesley D; Jourdan T; Szanda G; Mukhopadhyay B; Chedester L; Liow JS; Innis RB; Cheng K; Rice KC; Deschamps JR; Chorvat RJ; McElroy JF; Kunos G
    Cell Metab; 2012 Aug; 16(2):167-79. PubMed ID: 22841573
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New insights on the role of the endocannabinoid system in the regulation of energy balance.
    Gatta-Cherifi B; Cota D
    Int J Obes (Lond); 2016 Feb; 40(2):210-9. PubMed ID: 26374449
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval.
    Lindsley CW
    Curr Top Med Chem; 2008; 8(17):1553. PubMed ID: 19097323
    [No Abstract]   [Full Text] [Related]  

  • 75. The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity.
    Tran SB; Maxwell BD; Burrell R; Bonacorsi SJ
    J Labelled Comp Radiopharm; 2016 Dec; 59(14):665-672. PubMed ID: 27624665
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
    Yang Y; Miller KJ; Zhu Y; Hong Y; Tian Y; Murugesan N; Gu Z; O'Tanyi E; Keim WJ; Rohrbach KW; Johnghar S; Behnia K; Pelleymounter MA; Carlson KE; Ewing WR
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6856-60. PubMed ID: 21962575
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Anxiogenic and depressogenic side-effects of non-psychiatric drugs].
    Kirilly E; Gonda X; Juhász G; Bagdy G
    Orv Hetil; 2013 Aug; 154(34):1327-36. PubMed ID: 23955968
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A new perspective of cannabinoid 1 receptor antagonists: approaches toward peripheral CB1R blockers without crossing the blood-brain barrier.
    Wu YK; Yeh CF; Ly TW; Hung MS
    Curr Top Med Chem; 2011; 11(12):1421-9. PubMed ID: 21510837
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neuropsychiatric adverse effects of centrally acting antiobesity drugs.
    Nathan PJ; O'Neill BV; Napolitano A; Bullmore ET
    CNS Neurosci Ther; 2011 Oct; 17(5):490-505. PubMed ID: 21951371
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The therapeutic potential of second and third generation CB
    Cinar R; Iyer MR; Kunos G
    Pharmacol Ther; 2020 Apr; 208():107477. PubMed ID: 31926199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.